Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 13, 2017. The document serves as a transaction notification regarding the acquisition of ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively details specific share transactions executed on the London Stock Exchange (XLON) on January 12, 2017.
| Transaction Type | Instrument | Price per Share | Total Volume |
|---|---|---|---|
| Acquisition (Dividend Re-investment) | Ordinary Shares (25p each) | £15.7242 | 10,237 shares |
Note: The total volume is the aggregate of individual transactions listed below.
Material Changes and Transaction Details
The filing reports the following acquisitions of ordinary shares following the re-investment of dividends paid on January 12, 2017:
- Sir Andrew Witty (Chief Executive Officer): 7,299 shares.
- Lady C Witty (PCA of CEO): 2,078 shares.
- Mr J P Witty (PCA of CEO): 60 shares.
- Ms S Witty (PCA of CEO): 63 shares.
- Mr I W Whyte (PCA of Company Secretary): 500 shares.
- Mrs D Connor (PCA of President, Global Manufacturing & Supply): 237 shares.
All transactions were executed at a uniform price of £15.7242 per share.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, or contingencies. It is a regulatory disclosure of insider trading activity compliant with Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the total number of shares acquired by the CEO and associated family members (9,499 shares combined).
- Confirm the dividend re-investment plan (DRIP) execution date of January 12, 2017.
- Check the prevailing market price of GSK ordinary shares on the London Stock Exchange for January 12, 2017, to validate the transaction price of £15.7242.
- Review the company's annual report (Form 20-F) for broader financial performance data not included in this transaction notification.